The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis

Arthritis and Rheumatism

Volumn 50, Issue 10, 2004, Pages 3104-3111

  Morgan, Sarah L ^a   Oster, Robert A ^a   Lee, Jeannette Y ^a   Alarcón, Graciela S ^a   Baggott, Joseph E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENOSINE; FOLIC ACID; FOLINIC ACID; METHOTREXATE; PURINE;

ADULT; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PURINE METABOLISM; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; URINARY EXCRETION; URINE LEVEL; VITAMIN SUPPLEMENTATION;

ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE; ARTHRITIS, RHEUMATOID; ERYTHROCYTES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; PURINES; PYRIDOXINE; RIBONUCLEOTIDES; TREATMENT OUTCOME; VITAMIN B 12;

EID: 5644235310     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20516     Document Type: Article

References (47)

1. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
2. Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action [review]. Arthritis Rheum 1996;39:1951-60.
3. Cronstein BN. The mechanism of action of methotrexate [review]. Rheum Dis Clin North Am 1997;23:739-55.
4. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent [review]. J Appl Physiol 1994;76:5-13.
5. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991;88:2441-5.
6. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
7. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis [review]. Ann Rheum Dis 2001;60:729-35.
8. Baggott JE, Morgan SL, Ha TS, Alarcon GS, Koopman WJ, Krumdieck CL. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 1993;11 Suppl 8:S101-5.
9. Andersson SE, Johansson LH, Lexmuller K, Ekstrom GM. Antiarthritic effect of methotrexate: is it really mediated by adenosine? Eur J Pharm Sci 2000;9:333-43.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
12. Baggott JE, Morgan SL, Koopman WJ. The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum 1998;41:1407-10.
13. 12 deficient rats. Can J Biochem 1963;43:1367-74.
14. Linden J, Taylor HE, Feldman MD, Woodward EB, Ayers CR, Ripley ML, et al. The precise radioimmunoassay of adenosine: minimization of sample collection artifacts and immunocrossreactivity. Anal Biochem 1992;201:246-54.
15. Tamura T. Microbiological assay of folates. In: Picciano MF, Stokstad EL, Gregory JF, editors. Folic acid metabolism in health and disease. New York: Wiley-Liss; 1990. p. 121-37.
16. Cornwell PE, Morgan SL, Vaughn WH. Modification of a high-performance liquid chromatographic method for assay of homocysteine in human plasma. J Chromatogr 1993;617:136-9.
17. 12, pantothenic acid, biotin, and choline. Washington (DC): National Academy Press; 1998.
18. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25:441-6.
19. Morgan SL, Baggott JE, Tamura T. Relationship between plasma folate concentrations measured by radioassay and L. casei methods. FASEB J 1999;13:A229.
20. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
21. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
22. Lerin-Lozano C, Schnabel A, Erbsloh-Moller B, Gross WL. Is methotrexate plus cyclosporine A a useful salvage therapy for rheumatoid arthritis patients unresponsive to other types of methotrexate combination treatment? [letter]. Clin Exp Rheumatol 2002;20:737.
23. Gerards AH, Landewe RB, Prins AP, Bruijn GA, Goei The HS, Lann RF, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial [published erratum appears in Ann Rheum Dis 2003;62:1126]. Ann Rheum Dis 2003;62:291-6.
24. Gerards AH, Landewe RB, Prins AP, Bruijn GA, Goei The HS, Lann RF, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial [published erratum appears in Ann Rheum Dis 2003;62:1126]. Ann Rheum Dis 2003;62:291-6.
25. Bankhurst AD. Etanercept and methotrexate combination therapy. Clin Exp Rheumatol 1999;17(6 Suppl 18):S69-72.
26. Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor a antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17(6 Suppl 18):S73-7.
27. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
28. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [published erratum in Arthritis Rheum 2003;48:855]. Arthritis Rheum 2003;48:35-42.
29. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [published erratum in Arthritis Rheum 2003;48:855]. Arthritis Rheum 2003;48:35-42.
30. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493-9.
31. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patient with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
32. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988;31:906-8.
33. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Kiumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
34. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
35. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43.
36. Van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
37. Endresen GK, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis: an update and proposals for guidelines. Scand J Rheumatol 2001;30:129-34.
38. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized double-blind, placebo-controlled trial. Arthritis Rheum 1993;36:795-803.
39. Morgan SL, Baggott JE, Alarcon GS. Methotrexate in rheumatoid arthritis: folate supplementation should always be given. BioDrugs 1997;8:164-75.
40. Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6.
41. Hoekstra M, van de Laar MA, Bernelot Moens HJ, Kruijsen MW, Haagsma CJ. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol 2003;30:2325-9.
42. Physicians' desk reference. 57th edition. Montvale (NJ): Thomson PDR; 2003. p. 3418.
43. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:656-63.
44. Baggott JE, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999;135:813-7.
45. Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-7.
46. Laghi Pasini F, Capecchi PL, Di Perri T. Adenosine plasma levels after low dose methotrexate administration. J Rheumatol 1997;24:2492-3.
47. Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford) 1999;38:997-1002.